Margarita Labkovich

Dr. Margarita Labkovich

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Digital Health
Verified
Journal Article
Open access
MLMargarita Labkovich
Margarita Labkovich
MPMegan Paul
Megan Paul
EKEliott Kim
Eliott Kim
RSRandal A. Serafini
Randal A. Serafini
SLShreyas Lakhtakia
Shreyas Lakhtakia
EEEbrahim Elahi
Ebrahim Elahi
Vision impairment continues to be a major global problem, as the WHO estimates 2.2 billion people struggling with vision loss or blindness. One billion of these cases, however, can be prevented by expanding diagnostic capabilities. Direct global healthcare costs associated with these conditions totaled $255 billion in 2010, with a rapid upward projection to $294 billion in 2020. Accordingly, WHO proposed 2030 targets to enhance integration and patient-centered vision care by expanding refractive error and cataract worldwide coverage. Due to the limitations in cost and portability of adapted vision screening models, there is a clear need for new, more accessible vision testing tools in vision care. This comparative, systematic review highlights the need for new ophthalmic equipment and approaches while looking at existing and emerging technologies that could expand the capacity for disease identification and access to diagnostic tools. Specifically, the review focuses on portable hardware- and software-centered strategies that can be deployed in remote locations for detection of ophthalmic conditions and refractive error. Advancements in portable hardware, automated software screening tools, and big data-centric analytics, including machine learning, may provide an avenue for improving ophthalmic healthcare.

11 October 2022 in Research Square
Verified
Preprint
Open access
PDF file
MLMargarita Labkovich
Margarita Labkovich
AWAndrew Warburton
Andrew Warburton
CCChristopher Cheng
Christopher Cheng
OOOluwafeyikemi Okome
Oluwafeyikemi Okome
VNVicente Navarro
Vicente Navarro
JCJames Chelnis
James Chelnis
Background: Given global population growth and aging, it is imperative to prioritize early eye disease detection and treatment. However, the current eye specialist workforce capacity is not bridging the growing gap, making it important to consider alternative solutions for increasing eye screening capabilities. This study compared virtual reality (VR) vision screening exams that help evaluate retinal health, such as 24-2 perimetry, Ishihara color blindness, and Amsler grid tests, against their in-clinic counterparts. Methods: 86 subjects were recruited from Mount Sinai’s ophthalmology clinic for a head-to-head comparison trial that was internally controlled across healthy controls and eyes with glaucoma and retinal disease. Results: Perimetry results from Humphrey Visual Field Analyzer (HVFA) and VR suprathreshold testing demonstrated a good sensitivity both overall (80% OD, 84% OS) and across control (86% OD, 89% OS), glaucoma (69% OD, 78% OS), and retinal disease (76% OD, 80% OS) groups. A Garway-Heath anatomical map showed an overall 70-80% agreement. Ishihara plate tests did not show a significant difference between the two testing modalities (p = 0.12; Mann-Whitney U test), which remained true across groups. Amsler grid testing differences were also non-significant (p = 0.81; Mann-Whitney U test), including each subgroup. Patient time required to complete VR exams was significantly improved (p<0.0001; Wilcoxon) compared to the gold standard tests. Conclusions: All VR tests showed high sensitivity and percent agreement compared to in-office standards, indicating a promising potential for VR technologies in visual function screening for early identification of prevalent diseases such as glaucoma and retinal conditions.

24 July 2026 in American Journal of Ophthalmology Case Reports
Verified
Journal Article
Open access
MLMargarita Labkovich
Margarita Labkovich
PFPaul T Finger
Paul T Finger

Verified
Journal Article
Open access
PDF file
MLMargarita Labkovich
Margarita Labkovich
AWAndrew J Warburton
Andrew J Warburton
CCChristopher Cheng
Christopher Cheng
OOOluwafeyikemi Okome
Oluwafeyikemi Okome
VNVicente Navarro
Vicente Navarro
JCJames Chelnis
James Chelnis
Background: Given global population growth and aging, it is imperative to prioritize early eye disease detection and treatment. However, as patient volume increases, providers are facing a shortage of workforce capacity, particularly in areas where eye doctors are already scarce, making it important to consider alternative innovative solutions that could help increase eye screening capabilities. This study compared virtual reality (VR) platform of vision screening exams that are used to evaluate ocular health, such as 24-2 perimetry, Ishihara tiles, and the Amsler grid, against their in-clinic counterparts. Methods: A total of 86 subjects were recruited from Mount Sinai’s ophthalmology clinic (New York, USA) for a comparison trial that was internally controlled across healthy eyes and those with glaucoma and retinal diseases. VR and in-office tests were administered to the patients during their clinical visit, including 24-2 perimetry, Ishihara tiles, and the Amsler grid in a randomized order, and the results were compared for each test. Results: Perimetry results from Humphrey Visual Field Analyzer (HVFA) and VR suprathreshold testing demonstrated a good sensitivity both overall (80% OD, 84% OS) and across control (86% OD, 89% OS), glaucoma (69% OD, 78% OS), and retinal disease (76% OD, 80% OS) groups. A Garway-Heath anatomical map showed an overall 70–80% agreement. Ishihara plate tests did not show a significant difference between the two testing modalities (p = 0.12; Mann–Whitney U test), which remained true across all groups. Amsler grid testing differences were also non-significant within each subgroup (p = 0.81; Mann–Whitney U test). Patient time required to complete VR exams was significantly improved (p < 0.0001; Welch’s t-test) compared to the clinical standard tests. Conclusions: All VR-based exams tested in this study showed high sensitivity and percent agreement when compared to their in-office standards. Given the results of this study, VR has a promising potential in visual function screening, which, in addition to its portable design and easy use, could assist eye doctors in screening for prevalent diseases such as glaucoma and retinal conditions. Translational Relevance: VR-based vision exams that test vision fields, color vision and visual distortions provide comparable results in healthy patients, as well as those with glaucoma and retinal diseases, indicating its potential as a screening technology for different ocular pathologies. Given VR’s portable and low-profile features, it is important to consider leveraging VR to augment delivery of vision care.

Verified
Journal Article
Open access
PDF file
MLMargarita Labkovich
Margarita Labkovich
RSRandal Alexander Serafini
Randal Alexander Serafini
AWAndrew J Warburton
Andrew J Warburton
CCChristopher P Cheng
Christopher P Cheng
OOOluwafeyikemi Okome
Oluwafeyikemi Okome
JCJames G. Chelnis
James G. Chelnis
Background/Aims: This study set out to compare patient experiences and attitudes toward virtual reality (VR) versus in-office ophthalmic functional testing, as well as their eye exam visit preferences. Methods: A total of 64 patients undergoing a comparative clinical trial including VR and in-office versions of 24-2 visual field perimetry, Pelli–Robson contrast sensitivity, ETDRS visual acuity, Ishihara plates, and Amsler Grid tests were given a survey that included Likert-scaled questions regarding overall experience, speed, and comfort of broad VR testing versus in-office tests, as well as binary modality preference, like or dislike of various exam modality aspects, ease of understanding each test, distance traveled to their appointment, visit frequency, and remote care preferences. Results: In terms of overall experience, 59 (93.7%) participants rated VR as “Liked” or “Very Much Liked” compared to 38 (60.3%) for in-office tests (χ2 p < 0.0001). Regarding comfort, 59 (93.7%) and 38 (60.3%) participants at least “Liked” VR and in-office tests, respectively (χ2 p < 0.0001). For speed, 60 (95.2%) and 36 (57.1%) participants at least “Liked” VR and in-office tests, respectively (χ2 p < 0.0001). Accordingly, 11 (17.5%) patients liked all aspects of in-office tests, while 54 (85.7%) patients said the same for VR (χ2 p < 0.0001). Overall, 33 (52.4%) patients disliked something about in-office tests, while 20 (31.7%) said the same for VR (χ2 p < 0.0001). There were no differences in ability to understand tests between the two modalities. We noted a variable distribution of distance traveled and visits per year in our population, yet there was also a strong preference for implementing more remote eye testing options. Conclusions: Development and implementation of virtual reality analogs to in-office, functional ophthalmic exams can improve patient experience and facilitate remote care delivery.

7 August 2026 in American Journal of Ophthalmology Case Reports
Verified
Journal Article
Open access
MLMargarita Labkovich
Margarita Labkovich
PSParas Shah
Paras Shah
DBDaniel Barmas-Alamdari
Daniel Barmas-Alamdari
ADAlina Djougarian
Alina Djougarian
JLJung Min Lee
Jung Min Lee